William J. Febbo
William J. Febbo's purchase track record
William J. Febbo has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/12/2024 | OPRX | $100K | +45.0% | +205.3% | -0.1% |
| 8/19/2022 | OPRX | $251K | +29.3% | +12.6% | -3.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
OptimizeRx Expands Ad Reach via OpenPath Deal with The Trade Desk. OptimizeRx has announced a partnership with The Trade Desk that uses its OpenPath platform to add authenticated healthcare professional reach to the ad network. The deal is expected to broaden the company’s inventory and provide advertisers with more precise targeting in the healthcare space. This collaboration follows a series of moves to grow OptimizeRx’s presence in the digital advertising market.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
Modular Medical (MODD) Featured in After-Market Movers. Modular Medical was highlighted in a recent list of healthcare stocks moving during Friday's after-market session. The stock is currently trading near its support level, with an RSI of 39.0. This technical position provides context for the recent price activity noted in the news.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
LifeMD Announces Preferred Dividend and AT&T Partnership. LifeMD declared a quarterly dividend on its Series A cumulative perpetual preferred stock. The company also announced a partnership with AT&T that will provide free memberships, with the potential to convert some users into paying patients. These developments come as the common stock trades near its recent support level and the firm carries a high trailing P/E.
Transaction History
| MYO | ▲ Buy | Grant | 78,704 | $0 | 6/25/2026 | View on chart |
| MYO | ▲ Buy | Grant | 45,000 | $0 | 4/14/2026 | View on chart |
| OPRX | ▼ Sell | Tax Withholding | 401 | $3K | 2/14/2025 | View on chart |
| OPRX | ▲ Buy | Open Market | 20,000 | $100K | 12/12/2024 | View on chart |
| OPRX | ▲ Buy | Option Exercise | 28,895 | $0 | 4/18/2024 | View on chart |
| OPRX | ▼ Sell | Tax Withholding | 782 | $7K | 4/18/2024 | View on chart |
| OPRX | ▲ Buy | Grant | 60,000 | $0 | 4/15/2024 | View on chart |
| OPRX | ▲ Buy | Grant | 15,000 | $0 | 2/15/2024 | View on chart |
| OPRX | ▲ Buy | Option Exercise | 9,628 | $0 | 1/9/2024 | View on chart |
| OPRX | ▼ Sell | Tax Withholding | 2,884 | $38K | 1/9/2024 | View on chart |
| MODD | ▲ Buy | Grant | 2,500 | — | 6/30/2023 | View on chart |
| LFMD | ▲ Buy | Grant | 75,000 | $0 | 6/20/2023 | View on chart |
| MODD | ▲ Buy | Grant | 2,500 | — | 3/31/2023 | View on chart |
| OPRX | ▲ Buy | Option Exercise | 9,628 | — | 1/7/2023 | View on chart |
| MODD | ▲ Buy | Grant | 2,500 | — | 12/30/2022 | View on chart |
| MODD | ▲ Buy | Grant | 2,500 | — | 9/30/2022 | View on chart |
| OPRX | ▲ Buy | Open Market | 10,700 | $164K | 8/22/2022 | View on chart |
| OPRX | ▲ Buy | Open Market | 5,400 | $87K | 8/19/2022 | View on chart |
| MODD | ▲ Buy | Grant | 2,500 | — | 8/8/2022 | View on chart |
| MODD | ▲ Buy | Grant | 5,981 | — | 3/31/2022 | View on chart |
| MODD | ▲ Buy | Grant | 20,000 | $80K | 3/3/2022 | View on chart |
| OPRX | ▼ Sell | Open Market | 400 | $18K | 2/18/2022 | View on chart |
| OPRX | ▼ Sell | Open Market | 7,066 | $312K | 2/18/2022 | View on chart |
| OPRX | ▼ Sell | Open Market | 9,200 | $399K | 2/18/2022 | View on chart |
| MODD | ▲ Buy | Option Exercise | 45,586 | — | 2/14/2022 | View on chart |
| OPRX | ▼ Sell | Open Market | 8,226 | $391K | 1/18/2022 | View on chart |
| OPRX | ▼ Sell | Open Market | 8,140 | $382K | 1/18/2022 | View on chart |
| OPRX | ▼ Sell | Open Market | 300 | $15K | 1/18/2022 | View on chart |
| OPRX | ▼ Sell | Tax Withholding | 9,627 | — | 1/7/2022 | View on chart |
| MODD | ▲ Buy | Grant | 3,329 | — | 12/31/2021 | View on chart |
| OPRX | ▼ Sell | Open Market | 16,666 | $909K | 12/15/2021 | View on chart |
| OPRX | ▼ Sell | Open Market | 16,666 | $1.4M | 11/15/2021 | View on chart |
| OPRX | ▼ Sell | Open Market | 16,666 | $1.4M | 10/15/2021 | View on chart |
| MODD | ▲ Buy | Grant | 8,389 | — | 9/30/2021 | View on chart |
| OPRX | ▼ Sell | Open Market | 16,666 | $1.1M | 9/15/2021 | View on chart |
| OPRX | ▼ Sell | Gift | 8,600 | — | 9/13/2021 | View on chart |
| OPRX | ▼ Sell | Open Market | 16,666 | $1.0M | 8/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
MYO appoints Mary-Katherine McClure as Chief Commercial Officer
Myomo announced that Mary‑Katherine McClure has been named chief commercial officer. McClure will lead the company’s sales and marketing efforts and oversee commercial strategy. The addition of an experienced executive comes as the stock is trading near a long‑standing support level.
MYO appoints Mary-Katherine McClure as Chief Commercial Officer. Myomo announced that Mary‑Katherine McClure has been named chief commercial officer. McClure will lead the company’s sales and marketing efforts and oversee commercial strategy. The addition of an experienced executive comes as the stock is trading near a long‑standing support level.